Epigenetic Modulation of IL‐7 and IL‐10: Toward Personalized Immune Therapies in Viral Epidemics
Open Access
- 8 January 2026
- journal article
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1)
Abstract
Background: Host immune responses, including cytokine production, shape the severity of viral epidemics. Epigenetic mechanisms such as DNA methylation regulate cytokine gene expression and may contribute to immune dysregulation in severe disease. Methods: This study analyzed interleukin‐7 (IL‐7), IL‐8, and IL‐10 promoter methylation in 145 COVID‐19 patients (91 wards, 54 intensive care units (ICUs)), excluding 12 patients receiving epigenetically active drugs. Peripheral blood DNA underwent bisulfite conversion, followed by PCR and gel electrophoresis. Gene‐specific methylation levels were quantified using beta values. Results: IL‐7 was significantly hypermethylated overall (β = 0.835, p < 0.001), especially in ICU patients (β = 0.863, p = 0.001), independent of age, mortality, and malignancy. An interaction between age and ICU status indicated group‐specific effects. IL‐10 showed significant hypomethylation (β = 0.243, p < 0.001), while IL‐8 methylation did not differ significantly ( p = 0.373). ICU patients had higher mortality (26% vs 5.5%, p < 0.001). Conclusion: IL‐7 hypermethylation may impair T‐cell–mediated immunity in severe cases, while IL‐10 hypomethylation may reflect enhanced immunosuppression. These findings suggest a role for epigenetic cytokine regulation in disease progression and may guide future immunomodulatory strategies.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- DNA methylation as a transcriptional regulator of the immune systemTranslational Research, 2019
- Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1β on rheumatoid arthritis fibroblast-like synoviocytesArthritis Research & Therapy, 2018
- Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab ResistanceJournal of Clinical and Experimental Hematopathology, 2016
- Cisplatin in cancer therapy: Molecular mechanisms of actionEuropean Journal of Pharmacology, 2014
- Regulation of type I interferon responsesNature Reviews Immunology, 2013
- Harnessing the biology of IL-7 for therapeutic applicationNature Reviews Immunology, 2011
- FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancerAnnals of Oncology, 2010
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic MechanismCancer Research, 2009
- Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma modelCancer Immunology, Immunotherapy, 2002
- Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.2001